Johnson & Johnson 株価情報 (NYSE: JNJ)

最新ニュース Johnson & Johnson (NYSE:JNJ) 株価情報

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

News

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

B of A Securities analyst Tim Anderson maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and lowers the price target from $166 to $160.

Price Target

Analyst Ratings

B of A Securities Maintains Neutral on Johnson & Johnson, Lowers Price Target to $160

Johnson & Johnson's RYBREVANT Plus Chemotherapy Approved In Canada As First And Only Targeted Treatment To Reduce Risk Of Disease Progression Or Death By More Than Half In Second-Line EGFR-Mutated Advanced Lung Cancer

Johnson & Johnson Initiates Submission Of New Drug Application With FDA For TAR-200 In BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has fallen 6.85% since its last report. The company recently reported that it has 16.46 million shares sold short, which is 0.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736882118_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Johnson & Johnson's Recent Short Interest

Clinical research organization ICON plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) announced its financial guidance for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42971328/icon-issues-financial-guidance-for-full-year-2025" rel="noreferrer noopener">fiscal year 2025 on Tuesday</a>.
What Happened: The Dublin-based company forecasts revenues of $8.05 billion — $8.65 billion. This represents growth of about 1% at the midpoint compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $8.5 billion</a>.
The company expects adjusted earnings per share to be in the range of $13 to $15. That&#8217;s flat over the full-year 2024 adjusted earnings per share guidance midpoint compared to the consensus of $14.83.
See Also: <a href="https://www.benzinga.com/25/01/42980742/trump-off-hook-in-2020-election-case-special-counsel-smith-says-evidence-was-sufficient-to-obtain-and-sustain-a-conviction">Trump&#8217;s 2024 Election Win Spares Him From &#8216;Conviction&#8217; In Jan. 6 Case, Special Counsel Says</a>
ICON CEO Steve Cutler says trial activity has been &#8220;impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.&#8221; 
The company&#8217;s outlook for this year reflects an expected transition period, which includes a headwind from its top two customers on a combined basis, coupled with &#8220;an inconsistent recovery in biotech,&#8221; he added.
For fiscal year 2024, the company reaffirmed its current guidance of revenue of $8.26 billion — $8.3 billion and adjusted EPS of $13.90 &#8211; $14.10 versus consensus of $8.28 billion and $13.98, respectively.
Why It Matters: William Blair analysts are &#8220;surprised by the size of the topline cut relative to management&#8217;s initial thoughts last quarter (anticipated revenue growth in the low to mid-single digits for this year).&#8221;
Analyst Max Smock expects the company to face challenges in understanding &#8220;cautious spending patterns&#8221; from biopharma clients, including Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
There&#8217;s also uncertainty about when biotech demand will stabilize. Investors debate whether $14 or $15 per share was the right target for the quarter.
The initial guidance for next year will lean closer to $15, observers say. However, margins will face more pressure than expected.
Price Action: Icon stock is down 6.96% at $202.81 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" target="_blank" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Health Care

Movers

General

ICLR

Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty

On Monday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) agreed to acquire Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) for $132.00 per share in cash for a total equity value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940221/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-i" rel="noreferrer noopener">approximately $14.6 billion</a>.
Intra-Cellular Therapies is a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41752158/intra-cellular-therapies-treatment-reduces-schizophrenia-relapse-risk-63" rel="noreferrer noopener">Intra-Cellular Therapies&#8217; Treatment Reduces Schizophrenia Relapse Risk 63%</a>
With this agreement, Johnson &amp; Johnson adds Intra-Cellular Therapies&#8217; Caplyta&nbsp;(lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer&#8217;s disease-related psychosis and agitation, as well as a clinical-stage pipeline that further complements and strengthens Johnson &amp; Johnson&#8217;s current areas of focus.
In December 2024, Intra-Cellular Therapies submitted a marketing application to the FDA for Caplyta&nbsp;as an adjunctive treatment for adults with major depressive disorder (MDD).
In two global Phase 3 studies, Caplyta, as an adjunctive treatment to antidepressants, demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms, as measured by both clinician-rated and patient-reported outcomes.
If approved, Caplyta&nbsp;has the potential to be the first treatment approved for MDD and depressive symptoms associated with bipolar I and II in more than 15 years.
Additional Phase 3 trials are underway with Caplyta in bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania).
Johnson &amp; Johnson expects to fund the transaction through cash on hand and debt.
In 204, Bristol-Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) added an oral medication for&nbsp;schizophrenia via Karuna Therapeutics deal for $330 per share in cash for a total equity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">value of $14 billion</a>.
In November, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) released data from its two Phase 2 EMPOWER trials of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges" rel="noreferrer noopener">emraclidine for schizophrenia</a>.
The patients experienced an acute exacerbation of psychotic symptoms and did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics.
Price Action: JNJ stock is up 0.86% at $143.28, and ITCI stock is up 34.5% at $127.62 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42945266/why-department-store-chain-macys-stocks-are-sliding-on-monday-premarket" target="_blank" rel="noreferrer noopener">Why Is Department Store Chain Macy&#8217;s Stock Sliding Today?</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

ITCI

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal

Johnson &amp; Johnson expects to fund the transaction through a combination of cash on hand and debt. Johnson &amp; Johnson expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities of R&amp;D investment, competitive dividends, value-creating acquisitions, and strategic share repurchases.
Johnson &amp; Johnson will provide commentary on any potential impact to Adjusted Earnings Per Share (EPS) from the transaction when it provides its initial full year 2025 guidance during the fourth quarter earnings call on Wednesday, January 22, 2025.
 &nbsp;

Johnson & Johnson Says Intra-Cellular Acquisition Includes CAPLYTA (Lumateperone), The First And Only US FDA-Approved Treatment For Bipolar I And II Depression As An Adjunctive And Monotherapy

Johnson & Johnson Agrees To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For Total Equity Value Of $14.6B

Johnson & Johnson Has Agreed To Acquire Intra-cellular Therapies For $132.00 Per Share In Cash For A Total Equity Value Of Approximately $14.6B

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson &amp; Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep&#x2122;, powered by SOMAmer&#xAE; technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.

ILMN

Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis

<a href="https://www.bloomberg.com/news/articles/2025-01-12/johnson-johnson-exploring-bid-for-intra-cellular?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-01-12/johnson-johnson-exploring-bid-for-intra-cellular?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-01-12/johnson-johnson-exploring-bid-for-intra-cellular?embedded-checkout=true</a>

Bloomberg Reported Sunday, J&J Explores Bid For Intra-Cellular Therapies

On Wednesday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) said it has temporarily paused all U.S. cases using its Varipulse pulsed field ablation (PFA) system.
Pulsed-field ablation (PFA) is&nbsp;a non-thermal procedure that uses high-amplitude electrical pulses to treat cardiac arrhythmias (irregular heartbeat) and tumors.
In November, the FDA <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-medtech-receives-fda-approval-for-the-varipulse-pulsed-field-ablation-platform-for-the-treatment-of-atrial-fibrillation" rel="noreferrer noopener">approved</a> the Varipulse Platform for drug-refractory paroxysmal Atrial Fibrillation (AFib).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
The VARIPULSE Platform is designed to enable AFib treatment with a single device that combines PFA therapy and advanced mapping with the CARTO 3 System, a 3D electroanatomical cardiac mapping system.
"On January 5, out of an abundance of caution, Johnson &amp; Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. Varipulse cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation," the company <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-varipulse-u-s-external-evaluation" rel="noreferrer noopener">said</a>.
Neurovascular events are&nbsp;a range of conditions that affect the blood vessels and blood supply to the brain, spinal cord, and peripheral nerves.
Since the beginning of the external evaluation, the company has reported more than 130 cases of Varipulse in the U.S., spread across 14 sites and 40 operators. Globally, it has reported more than 3,000 commercial cases with Varipulse.
"We are working diligently to complete the investigation according to our medical safety processes and resume the U.S. External Evaluation," the company said in its statement. "We expect to have more information to communicate within the coming days."
Last month, the FDA issued a complete response letter (CRL) to&nbsp;Johnson &amp; Johnson's Biologics License Application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration in patients with non-small cell lung cancer with epidermal growth <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42535810/fda-rejects-johnson-johnsons-injectable-version-of-approved-drug-for-lung-cancer" rel="noreferrer noopener">factor receptor mutations</a>.
The CRL is&nbsp;related&nbsp;to observations as part of a standard pre-approval inspection at a manufacturing facility.
Price Action: JNJ stock closed at $146.23 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42897109/british-retail-giant-marks-spencer-warns-of-economic-challenges-despite-strong-sales-growth-in-food-and-retail" target="_blank" rel="noreferrer noopener">British Retail Giant Marks &amp; Spencer Warns Of Economic Challenges Despite Strong Sales Growth In Food And Retail</a></li>
</ul>
Photo by Tada Images via Shutterstock

Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events

Johnson & Johnson Says Nipocalimab BLA Received FDA Priority Review Designation For Treatment Of Antibody Positive Patients With Generalized Myasthenia Gravis

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$142.00</td>
<td>$132.6K</td>
<td>236</td>
<td>1.1K</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$35.0K</td>
<td>3.7K</td>
<td>750</td>
</tr>
<tr>
<td>SOLV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$70.00</td>
<td>$25.0K</td>
<td>711</td>
<td>608</td>
</tr>
<tr>
<td>GEHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$92.50</td>
<td>$83.4K</td>
<td>14</td>
<td>340</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$210.00</td>
<td>$87.3K</td>
<td>2.5K</td>
<td>284</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$45.00</td>
<td>$28.6K</td>
<td>53.7K</td>
<td>193</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$110.00</td>
<td>$106.5K</td>
<td>210</td>
<td>101</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$220.00</td>
<td>$64.2K</td>
<td>184</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option trade with neutral sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 829 contract(s) at a $142.00 strike. The total cost received by the writing party (or parties) was $132.6K, with a price of $160.0 per contract. There were 236 open contracts at this strike prior to today, and today 1103 contract(s) were bought and sold. 
• For CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on January 17, 2025. This event was a transfer of 250 contract(s) at a $15.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3727 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding SOLV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $250.0 per contract. There were 711 open contracts at this strike prior to today, and today 608 contract(s) were bought and sold. 
• For GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we notice a call option sweep that happens to be bearish, expiring in 254 day(s) on September 19, 2025. This event was a transfer of 139 contract(s) at a $92.50 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $83.4K, with a price of $600.0 per contract. There were 14 open contracts at this strike prior to today, and today 340 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bullish sentiment. It expires in 373 day(s) on January 16, 2026. Parties traded 148 contract(s) at a $210.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $87.3K, with a price of $590.0 per contract. There were 2546 open contracts at this strike prior to today, and today 284 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option trade that happens to be bullish, expiring in 44 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $28.6K, with a price of $286.0 per contract. There were 53788 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 254 day(s) on September 19, 2025. Parties traded 101 contract(s) at a $110.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1055.0 per contract. There were 210 open contracts at this strike prior to today, and today 101 contract(s) were bought and sold. 
• For VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we notice a call option trade that happens to be neutral, expiring in 373 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $64.2K, with a price of $3210.0 per contract. There were 184 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

CAPR

GEHC

SOLV

VEEV

8 Health Care Stocks Whale Activity In Today's Session

Johnson & Johnson's Posdinemab And Tau Active Immunotherapy Granted FDA Fast Track Designations For Alzheimer's

Median overall survival improvement expected to exceed one year
First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
RARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT&#xAE; (amivantamab-vmjw) plus LAZCLUZE&#x2122; (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The chemotherapy-free combination regimen met the final pre-specified secondary endpoint of OS and demonstrated clinically meaningful and statistically significant improvement in OS versus the current standard of care osimertinib. Improvement in median OS is expected to exceed one year.

Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen With A Survival Benefit Over Current Standard Of Care In First-line Treatment Of EGFR-Mutated Lung Cancer

Shares of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are flat in Monday's trading. But they continue to test support. If this support breaks, it could be bearish for the entire market. This is why we have made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
The S&amp;P 500 Index consists of 11 sectors. At varying times, each sector can have more influence on the broader markets than others. Right now, health care is important.
Within these sectors, different stocks can have more influence on them than others at different times. That's the case now with the healthcare sector and JNJ.
As you can see on the chart, $143.50 has been support for Johnson &amp; Johnson and it is now trading close to this level. If this support breaks, it could pull the healthcare sector lower. And this could pull the entire stock market down along with it.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06122909/1-1-1024x563.png" alt="" class="wp-image-720225" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06122909/1-1-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06122909/1-1-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06122909/1-1-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06122909/1-1.png 1486w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/25/01/42810114/openai-ceo-sam-altman-reveals-company-struggling-with-chatgpt-pro-losses">OpenAI CEO Sam Altman Says Company Losing Money On ChatGPT Pro Plan</a>
It isn't a coincidence that there is support at this level. It was support in April. Then it was support in May and June and now it is support again.
Support forming at prices that had previously been support is a common occurrence in the financial markets. It is a result of investor and trader psychology.
It is due to ‘seller's remorse'.
Some who sold their shares at the support level come to regret doing so if the price rallies soon after. Some of these remorseful sellers decide that if possible, they will buy their shares back at the same price they were sold at.
As a result, if and when the stock eventually reverses and drops back to the selling price, they place buy orders. If there is a sufficient quantity of these orders, it will cause support to form at the level again.
That's the case with the $143.50 level for Johnson &amp; Johnson.
If a stock trades and stays below the support, traders say that the support has ‘broken'. This isn't merely symbolic. It illustrates an important market dynamic.
It means that the traders and investors who created the support with their buy orders have left the market. They have finished or canceled their orders.
This is bearish because those who wish to sell will have to push the stock lower to draw buyers into to market to get their orders executed. This could force it into a new downtrend.
It may be about to happen with Johnson &amp; Johnson. This could bring the healthcare sector lower and put downward pressure on the entire stock market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42806662/justin-trudeau-set-to-resign-as-prime-minister-of-canada-report">Justin Trudeau Set To Resign As Prime Minister Of Canada: Report</a></li>
</ul>
Image: Shutterstock

Stock Of The Day: Will Johnson & Johnson Take The Market Lower?

Deep-pocketed investors have adopted a bearish approach towards Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JNJ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Johnson &amp; Johnson. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 55% bearish. Among these notable options, 2 are puts, totaling $63,388, and 7 are calls, amounting to $254,697.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $150.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Johnson &amp; Johnson's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Johnson &amp; Johnson's whale trades within a strike price range from $130.0 to $150.0 in the last 30 days. 
<h3>Johnson &amp; Johnson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735840834_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$26.05</td>
<td>$25.0</td>
<td>$25.4</td>
<td>$130.00</td>
<td>$50.8K</td>
<td>31</td>
<td align="right">54</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$25.65</td>
<td>$25.25</td>
<td>$25.3</td>
<td>$130.00</td>
<td>$50.6K</td>
<td>31</td>
<td align="right">94</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.4</td>
<td>$13.0</td>
<td>$13.26</td>
<td>$140.00</td>
<td>$39.7K</td>
<td>53</td>
<td align="right">30</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.15</td>
<td>$8.0</td>
<td>$8.15</td>
<td>$140.00</td>
<td>$31.7K</td>
<td>1.7K</td>
<td align="right">39</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$15.8</td>
<td>$15.15</td>
<td>$15.8</td>
<td>$150.00</td>
<td>$31.6K</td>
<td>116</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Johnson &amp; Johnson</h3>
<ul>
<li>With a volume of 1,969,865, the price of JNJ is down -0.2% at $144.33. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $170.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $166. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Johnson &amp; Johnson, targeting a price of $175. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson &amp; Johnson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Markets

Smart Money Is Betting Big In JNJ Options

Rep. Marjorie Taylor Greene (R-Ga.) disclosed recent purchases of several stocks on Christmas Eve, according to <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene">Benzinga Government Trades.</a>
Here's a look at what the far-right politician bought.
What Happened: Greene has been an active trader of stocks while in Congress, based on her disclosures over the years.
After going several years without disclosing any trades, Greene <a href="https://www.benzinga.com/markets/equities/24/05/38611874/marjorie-taylor-greene-reveals-new-stock-trades-after-2-year-gap-berkshire-hathway-goldman-sachs">disclosed several purchases</a> in May. She also made<a href="https://www.benzinga.com/government/24/11/41754747/is-marjorie-taylor-greene-betting-on-trump-victory-buys-apple-meta-tesla-stocks-ahead-of-2024-electi"> multiple transactions</a> later in September, October and November.
Greene recently disclosed multiple stock purchases that happened on Dec. 24. Here are the trades that she made, with each valued between $1,000 and $15,000:
<ul>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</li>
<li>Johnson and Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>)</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
</ul>
Of these stocks bought in the latest disclosures, Eli Lilly, Gilead and Norfolk Southern are new buys for Greene over the last two years.
The rest of the stocks are already owned by Greene with her adding to her position. Several of the stocks, like Hershey have been bought four times by Greene in 2024.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The trading activity of <a href="https://www.benzinga.com/topic/congress-trading">members of Congress </a>continues to be a hot-button item closely monitored by retail investors and the public.
President Joe Biden <a href="https://www.benzinga.com/24/12/42538504/biden-endorses-ban-of-congressional-stock-trading-nobody-in-the-congress-should-be-able-to-make-money-in-the-stock-market-while-in-office">endorsed a ban</a>, suggesting Congress members shouldn&#8217;t be able to trade stocks and options while in office.
&#8220;Nobody in the Congress should be able to make money in the stock market while they&#8217;re in the Congress,&#8221; Biden said in an interview with political advisor&nbsp;Faiz Shakir.
There have been numerous calls to vote for Congress members to vote for a ban on Congressional trading, but a vote has not happened. Representative&nbsp;Ro Khanna&nbsp;(D-Calif.)&nbsp;<a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin" target="_blank" rel="noreferrer noopener">previously told Benzinga&nbsp;</a>that he will continue to advocate for a vote to ban the practice.
Congressional committee assignments can create conflicts of interest when trades are disclosed. Greene serves on the House Subcommittee on Cybersecurity, Information Technology, and Government Innovation, which could give her information on government contracts for technology companies.
Greene's latest stock purchases in November and the new disclosures show a continued bet on technology stocks going forward. Chip stocks and technology companies were among&nbsp;<a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r" target="_blank" rel="noreferrer noopener">the best performing&nbsp;</a>in the S&amp;P 500 in 2017, Trump&#8217;s first year in the White House previously.
Tech giants Meta and Microsoft remain popular for Greene in 2024 with multiple purchases made. A pending ban of TikTok could benefit Meta in 2025.
Greene is also positioning her portfolio with several healthcare names like Eli Lilly, Gilead and Johnson and Johnson.
A deal between Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) and Hershey could benefit Greene if the chocolate company <a href="https://www.benzinga.com/ma/24/12/42496403/deal-dispatch-hershey-monelez-houlihan-intevac-onion-infowars">approves an acquisition</a>.
While Greene has been actively buying stocks over the last several months, she has not reported selling her shares of Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), the Trump co-founded media company that completed a SPAC merger earlier this year.
Greene <a href="https://www.benzinga.com/government/24/09/41031499/marjorie-taylor-greene-stays-loyal-to-trump-keeps-djt-stock-buys-into-warren-buffetts-berkshire-in-l">disclosed buying</a>&nbsp;Digital World Acquisition&nbsp;shares back in October 2021, the SPAC that took&nbsp;Trump's&nbsp;media company public in March 2024.
The transaction was done with shares trading between $67.96 to $118.80. A tweet from UnusualWhales pins the purchase price at $94.20, meaning Greene is down significantly on her $15,000 to $50,000 purchase in the Trump-linked stock. Shares of DJT trade at $39.13 at the time of writing.
Previous disclosures by Greene have shown buys of Tesla and Berkshire Hathaway stock. Greene's portfolio currently consists of investments tied to some of the richest people in the world including Elon Musk, Warren Buffett, Jeff Bezos, Mark Zuckerberg and Jensen Huang. Her portfolio also has exposure to Trump via his media company.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/01/36459015/10-best-stock-traders-in-congress-in-2023-spoiler-nancy-pelosi-is-back-on-the-list">10 Best Stock Traders In Congress In 2023 (Spoiler: Nancy Pelosi Has Reentered The Chat)</a></li>
</ul>
Image: Shutterstock

Politics

ADBE

AMAT

AMZN

GILD

MDLZ

MSFT

NVDA

Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday

BofA analyst Tim Anderson lowered the firm's price target on Johnson & Johnson to $160 from $166 and keeps a Neutral rating on the shares. The firm...

Johnson & Johnson price target lowered to $160 from $166 at BofA

Mayar Capital Q2 2024 Letter To Partners

Argenx cut to Sell at Deutsche Bank on valuation

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

Odyssey Therapeutics files for $100M IPO

The stock market has been volatile to kick off 2025, with many top tech stocks well off their highs as some investors question their lofty valuatio...

Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more... The pharmaceutical sector plays a crucial role in tackling global health issues, from combating infectious diseases to addressing chronic illnesses. The companies in this sector are not only developing groundbreaking treatments but also improving access to life-saving drugs.
Amid this backdrop, investors looking to tap into the pharmaceutical sector might consider buying these three fundamentally strong pharma stocks Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), and Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>) for potential gain.
As the world faces rising healthcare demands, innovative pharmaceutical firms are stepping up to meet these challenges. Technological advancements such as AI-driven drug discovery and precision medicine enable faster development of treatments and personalized care, <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality">addressing the unique needs of individual patients</a>. Pharmaceutical manufacturers are already using Gen AI foundational models to identify targets, develop validation assays, and assist in preclinical testing to determine their effectiveness.
One of the key drivers of growth in the pharmaceutical sector is the rising prevalence of non-communicable diseases such as diabetes, cardiovascular conditions, and cancer. Companies investing in advanced therapies, including biologics and gene editing, are positioned to benefit from this trend. With <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">50 novel drugs approved by the U.S. Food and Drug Administration (FDA)</a> in 2024, the pharmaceutical sector is likely to see sustained growth and long-term relevance.
Furthermore, the U.S. pharmaceutical market is anticipated to reach $764.06 billion by 2033, <a href="https://www.grandviewresearch.com/industry-analysis/us-pharmaceuticals-market-report#:~:text=The%20U.S.pharmaceutical%20market%20is%20expected%20to%20grow%20at%20a,USD%200.76%20billion%20by%202030.">exhibiting a CAGR of 5.5%</a>.
Now, let us dive deep into the fundamentals of three <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> stocks, starting with third.
Stock #3: Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE is a global leader in biopharmaceuticals, offering a wide range of medicines and vaccines across several therapeutic areas. Its diverse portfolio spans treatments for cardiovascular conditions, metabolic issues, migraines, women's health, and infectious diseases, including COVID-19 prevention and treatment. It also explores future mRNA and antiviral therapies and provides biosimilars for chronic immune and inflammatory conditions.
On December 20, PFE received approval from the U.S. Food and Drug Administration (FDA) for BRAFTOVI&#xAE; (encorafenib) in combination with cetuximab and mFOLFOX6 for the treatment of patients with BRAF V600E-Mutant metastatic colorectal cancer. This approval is first-in-line in the development of innovative medicines for the hardest-to-treat cancers, also expanding PFE's portfolio.
Moreover, on November 20, PFE announced that it received approval from the European Commission (EC) for HYMPAVZI for the routine prevention of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A without FVIII inhibitors or severe hemophilia B without FIX inhibitors. this approval will strengthen PFE's position in the genetic disease treatment market as HYMPAVZI is the first and only anti-tissue factor pathway inhibitor approved by EC.
PFE pays a $1.72 per share dividend annually, translating to a 6.72% yield on the current share price. Its four-year dividend yield is 4.32%.
PFE's total revenues for the third quarter (ended September 30, 2024) increased 31.2% year-over-year to $17.70 billion. The company's non-GAAP net income stood at $6.05 billion compared to the prior-year quarter's loss of $968 million, while its <a href="https://www.investopedia.com/terms/e/eps.asp">earnings per share</a> came in at $1.06 versus a loss of $0.17 per share last year.
As a result of its impressive performance, the company updated its fiscal year 2024 financial guidance, increasing its revenue projection to a range of $61 billion to $64 billion, up from the previous estimate of $59.50 billion to $62.50 billion. Additionally, it has raised its adjusted EPS guidance to a new range of $2.75 to $2.95, higher than the prior forecast of $2.45 to $2.65.
Analysts expect PFE's revenue for the fourth quarter (ended December 2024) to grow 20.3% year-over-year to $17.14 billion, while its EPS for the same period is expected to increase 360.4% from the prior year-quarter to $0.46. Moreover, the company has surpassed Street revenue and EPS estimates in three of the trailing four quarters.
Shares of PFE have surged 4.5% over the past month to close the last trading session at $26.72.
PFE's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
PFE has an A grade for Growth and a B for Value. It is ranked #34 out of 151 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to see the additional ratings for PFE (Momentum, Stability, Sentiment, and Quality).
Stock #2: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ is engaged in the research and development, manufacture, and sale of healthcare products primarily focused on human health and well-being. The company offers a diversified range of products through the Innovative Medicine segment and MedTech segment.
On January 10, JNJ announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH&#x2122; SF Catheter for the treatment of cardiac arrhythmias. This offers electrophysiologists the ability to switch between radiofrequency and pulsed field energy in a single, fully integrated catheter, delivering safe and effective procedures for patients.
On December 30, JNJ announced that it had received the European Commission approval for RYBREVANT&#xAE; (amivantamab) in combination with LAZCLUZE&#x2122; (lazertinib) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults with EGFR mutations. This multitargeted, chemotherapy-free combination as shown superior efficacy compared to Osimertinib monotherapy for treating EGFR-mutated NSCLC.
For the nine-month period that ended September 30, 2024, JNJ's sales to customers increased 4% year-over-year to $66.30 billion. Its gross profit rose 4.5% from the year-ago value to $45.96 billion. The company's net earnings from continuing operations amounted to $6.84 billion, representing a 15.7% increase from the same period last year. Also, its net earnings per share from continuing operations for the period increased 24.1% year-over-year to $4.38.
JNJ's revised outlook for the fiscal year 2024 anticipates operational sales in the range of $89.40 billion to $89.80 billion, marking a 6.6% growth compared to 2023, largely fueled by recent acquisitions. The company also projects adjusted EPS between $9.88 and $9.98.
Street expects JNJ's revenue for the fiscal year (ended December 2024) to increase 4.3% year-over-year to $88.78 billion. Its EPS for the same year is expected to register a marginal growth from the prior year, settling at $9.96.
JNJ shares have declined marginally intraday, closing the last trading session at $142.06.
JNJ's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
JNJ has a B grade for Value, Stability, Sentiment, and Quality. It is ranked #14 in the same industry.
<a href="https://stocknews.com/stock/JNJ/">Click here</a> to see the additional ratings for JNJ (Growth and Momentum).
Stock #1: Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK is a global healthcare company offering health solutions through its prescription medicines, including biological therapies, vaccines, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.
On January 8, MRK announced the National Medical Products Administration (NMPA) of China approved GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine] for use in males aged 9 to 26. This approval makes GARDASIL the first HPV vaccine in China, helping MRK strengthen its position.
On December 20, MRK announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. This agreement will allow MRK to develop, manufacture, and commercialize LM-299.
During the nine-month period ended September 30, 2024, MRK's sales increased 6.7% year-over-year to $48.54 billion, while its pharmaceutical segment's sales improved by 7.2% from the prior year's value to $43.36 billion. The company's net income attributable rose significantly from the year-ago value to $13.37 billion, while its EPS stood at $5.26, up considerably year-over-year.
According to the full-year 2024 guidance, MRK forecasts worldwide sales to range from $63.60 billion to $64.10 billion, an increase from the previous guidance of $63.40 billion to $64.40 billion. The company also expects non-GAAP EPS to be between $7.72 and $7.77.
The consensus revenue estimate of $15.52 billion for the fiscal fourth quarter (ending December 2024) represents a 6.1% increase year-over-year. The consensus EPS estimate of $1.79 for the current quarter indicates a considerable improvement year-over-year.
The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
The stock declined marginally intraday, closing the last trading session at $99.25.
MRK's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Quality and a B for Value and Stability. Within the same industry, it is ranked #10.
<a href="https://stocknews.com/stock/MRK/">Click here</a> to see MRK's ratings for Growth, Momentum, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
&nbsp;

<hr />
JNJ shares were trading at $143.12 per share on Monday morning, up $1.06 (+0.75%). Year-to-date, JNJ has declined -1.04%, versus a -1.64% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/jnj-mrk-pfe-3-pharmaceutical-stocks-addressing-global-health-challenges/>3 Pharmaceutical Stocks Addressing Global Health Challenges</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharmaceutical Stocks Addressing Global Health Challenges

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from analysts. Read more… When markets get unpredictable, many investors turn to blue-chip stocks for stability. These companies are known for their solid financials, steady growth, and reliable dividends, making them a wise choice for anyone looking to weather economic ups and downs.
Below, I have highlighted three fundamentally strong blue-chip stocks from the healthcare and pharmaceutical sector: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), and Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>) that one could consider investing in the near term.
Healthcare stocks, in particular, have a reputation for being dependable. They often hold up well during tough economic times because the need for healthcare doesn't go away, no matter what the market is doing. In fact, healthcare is the third-largest industry in the S&amp;P 500, and it's poised for growth. PwC expects medical costs to <a href="https://www.pwc.com/us/en/industries/health-industries/library/behind-the-numbers.html">rise 8% in 2025</a> for group markets, driven by inflation, prescription drug spending, and higher demand for mental health services.
At the same time, inflation persists. In November, consumer prices <a href="https://www.cnbc.com/2024/12/11/cpi-inflation-november-2024-annual-inflation-rate-accelerates-to-2point7percent-in-november-as-expected.html">rose at a 2.7%</a> annual rate, slightly higher than in October. As a result, the Federal Open Market Committee adjusted its monetary policy, cutting the overnight borrowing rate to a target range of 4.25%-4.5%. With uncertainty looming over the stock market, investors can look to invest in blue-chip stocks that offer stability, value, and diversification, shielding investments from potential downturns.
With that in mind, let's evaluate the three <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> picks, beginning with the third choice.
Stock #3: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ is engaged in researching, developing, manufacturing, and selling healthcare products primarily focused on human health and well-being. The company offers a diversified range of products through the Innovative Medicine and MedTech segments.
On December 30, 2024, JNJ announced that the European Commission approved RYBREVANT&#xAE; (amivantamab) in combination with LAZCLUZE&#x2122; (lazertinib) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults with EGFR mutations. This chemotherapy-free combination has shown superior efficacy compared to Osimertinib monotherapy for treating EGFR-mutated NSCLC.
Last year, in August, JNJ acquired V-Wave Ltd., a privately held company specializing in innovative heart failure treatment. The deal included an upfront payment of $60 million, with the potential for additional payments of up to $1.1 billion. This acquisition is set to enhance JNJ MedTech's position in the cardiovascular space, broadening its portfolio of advanced heart failure treatment options.
For the third quarter of 2024, which ended on September 29, JNJ's sales to customers increased 5.2% year-over-year to $22.47 billion. Its gross profit rose 5.2% from the year-ago value to $15.51 billion, while its adjusted net earnings from continuing operations amounted to $5.88 billion or $2.42 per share in the same period. Also, the company's <a href="https://www.investopedia.com/terms/f/freecashflow.asp">free cash flow</a> for the quarter increased 16.9% year-over-year to $14 billion.
As per the updated guidance for the fiscal year 2024, JNJ forecasts operational sales between $89.20 billion and $89.60 billion, a 6% increase from 2023, primarily driven by recent acquisitions. The company also expects adjusted EPS between $9.97 and $10.07.
The consensus revenue estimate of $88.79 billion for the fiscal year 2024, which ended on December 31, represents a 4.3% increase year-over-year. The consensus EPS estimate of $9.96 for the same period indicates a marginal improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
The stock has gained 1.1% year-to-date to close the last trading session at $146.23.
JNJ's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
JNJ has a B grade for Value, Stability, Sentiment, and Quality. It is ranked #14 out of 152 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/JNJ/">Click here</a> to see the additional ratings for JNJ (Growth and Momentum).
Stock #2: Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK is a global healthcare company offering health solutions through its prescription medicines, including biologic therapies, vaccines, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.
On January 8, 2025, MRK announced that China's National Medical Products Administration (NMPA) has approved GARDASIL&#xAE; (Human Papillomavirus Quadrivalent Vaccine, Types 6, 11, 16, and 18) for use in males aged 9 to 26. With this approval, GARDASIL became the first HPV vaccine authorized in China for preventing HPV-related cancers and diseases in males.
On November 19, the company's board of directors declared a quarterly dividend of $0.81 per share of the company's common stock for the first quarter of 2025. This dividend was paid to its shareholders on January 8, 2025.
With 14 years of consecutive dividend growth, MRK's annual dividend of $3.24 translates to a yield of 3.21% on the current share price. Its four-year average yield is 2.87%. The company's dividend payout has grown at a CAGR of 6.1% over the past three years.
MRK's sales for the third quarter ended September 30, 2024, increased 4.4% year-over-year to $16.66 billion, while its KEYTRUDA product sales improved by 17.2% from the year-ago value to $ 7.43 billion. The company's non-GAAP net income and non-GAAP EPS for the quarter stood at $3.98 billion and $1.57, respectively.
According to the full-year 2024 guidance, MRK forecasts worldwide sales to range from $63.60 billion to $64.10 billion, an increase from the previous guidance of $63.40 billion to $64.40 billion. The company also expects non-GAAP EPS to be between $7.72 and $7.77.
Analysts expect MRK's revenue for the fourth quarter (ended December 2024) to increase 5.9% year-over-year to $15.49 billion, while its EPS for the same period is expected to grow significantly from the prior year to $1.80. Moreover, the company topped the consensus revenue estimates in each of the trailing four quarters.
The stock has gained marginally year-to-date to close the last trading session at $99.85.
It is no surprise that MRK has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It also has an A grade for Quality and a B for Value and Stability. Within the same industry, it is ranked #8 out of 152 stocks.
In addition to the POWR Rating grades I've just highlighted, you can see MRK's Growth, Momentum, and Sentiment ratings <a href="https://stocknews.com/stock/MRK/">here</a>.
Stock #1: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV is a global diversified research-based biopharmaceutical company engaged in manufacturing and selling medications and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties.
On December 13, 2024, ABBV announced the acquisition of Nimble Therapeutics to strengthen its immunology pipeline further. The deal includes Nimble's lead asset, an investigational oral peptide IL-23R inhibitor currently in preclinical development for psoriasis, as well as a pipeline of innovative oral peptide candidates targeting various autoimmune diseases with significant unmet needs.
Additionally, ABBV will gain access to Nimble's proprietary peptide synthesis, screening, and optimization platform, designed to enable the discovery and optimization of oral peptide therapeutics.
On October 30, the company's board of directors increased the quarterly dividend from $1.55 to $1.64 per share, payable on February 14, 2025 to the shareholders of record on January 15, 2025. This reflects an increase of approximately 5.8%, continuing ABBV's strong commitment to returning cash to shareholders through a growing dividend.
It pays an annual dividend of $6.56, which translates to a yield of 3.65% at the current share price. Its four-year average dividend yield is 3.89%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 7.7% over the past five years.
During the fiscal third quarter (ended September 30, 2024), ABBV's net revenue increased 3.8% year-over-year to $14.46 billion, while the company's Neuroscience segment reported net revenue of $2.36 billion, indicating a 15.6% growth from the prior-year quarter. ABBV's operating earnings came in at $3.83 billion, up 67.9% year-over-year, while its adjusted earnings per share grew 1.7% from the year-ago value to $3.
Looking ahead, ABBV forecasts full-year 2024 and raises its adjusted EPS to range between $10.90 and $10.94, from the prior forecast of $10.67 and $10.87.
Street expects ABBV's revenue and EPS for the fiscal fourth quarter (ended December 2024) to increase 3.5% and 3.4% year-over-year to $14.80 billion and $2.88, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Shares of ABBV have gained 6.7% over the past six months and 10.1% over the past year to close the last trading session at $178.50.
ABBV's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has a B grade for Growth, Value, Stability, Sentiment, and Quality. Out of 152 stocks in the Medical - Pharmaceuticals industry, ABBV is ranked #3. <a href="https://stocknews.com/stock/ABBV/">Click here</a> to see ABBV's rating for Momentum.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares fell $0.01 (-0.01%) in after-hours trading Wednesday. Year-to-date, JNJ has declined -1.62%, versus a 0.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/jnj-abbv-mrk-3-blue-chip-stocks-with-strong-buy-ratings-from-analysts/>3 Blue-Chip Stocks with Strong Buy Ratings from Analysts</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Blue-Chip Stocks with Strong Buy Ratings from Analysts

Dividend Aristocrats are a shield during market turbulence and a key to diversified growth. Therefore, investors looking for stability and dependable income might consider adding fundamentally stable stocks Johnson & Johnson (JNJ), PepsiCo (PEP), and Kimberly-Clark (KMB). Continue reading… Dividend Aristocrats are companies with a track record of increasing dividends for 25 consecutive years or more and are often considered a cornerstone of a reliable investment strategy. These stocks belong to stable, well-established companies that can weather economic downturns while rewarding shareholders with consistent payouts.
Amid this backdrop, it could be wise to scoop up shares of dividend aristocrats stocks Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), PepsiCo, Inc. (<a href="https://stocknews.com/stock/PEP/">PEP</a>), and Kimberly-Clark Corporation (<a href="https://stocknews.com/stock/KMB/">KMB</a>) for their resilience and long-term gains.
In the third quarter of 2024, <a href="https://www.bea.gov/news/2024/gross-domestic-product-third-estimate-corporate-profits-revised-estimate-and-gdp-1">real GDP increased at an annual rate of 3.1%</a> year-over-year. This shift was due to factors like increased consumer spending, exports, federal government spending, and a rise in business investment.
Investors are drawn to Dividend Aristocrats for their ability to provide a stable income stream, which can <a href="https://www.investopedia.com/terms/d/dividend-aristocrat.asp">act as a cushion during volatile market conditions</a>. Further, dividend aristocrats often outperform during bear markets, owing to their defensive nature that helps preserve capital, as many of these companies operate in non-cyclical industries like healthcare, consumer staples, and utilities.
With that in mind, let's delve into the fundamentals of the above-mentioned three Dividend Aristocrat picks.
Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ is engaged in the research and development, manufacture, and sale of healthcare products primarily focused on human health and well-being. The company offers a diversified range of products through the Innovative Medicine segment and MedTech segment.
On January 2, the company declared a quarterly <a href="https://www.investopedia.com/terms/d/dividend.asp">dividend</a> of $1.24 per share, payable on March 4, to shareholders of record on February 18. With 62 years of consecutive dividend growth, JNJ pays an annual dividend of $4.96, which translates to a yield of 3.44% at the current share price. Its four-year average dividend yield is 2.74%. Also, the company's dividend payouts have increased at a CAGR of 5.5% over the past five years.
On December 2, JNJ announced that it received the U.S. Food and Drug Administration (FDA) approval for a first-of-its-kind silicone gel-filled implant, MENTOR&#x2122; MemoryGel&#x2122; Enhance Breast Implants. This launch is the first and only implant line created specifically for women with larger breast cup sizes undergoing breast reconstruction and reconstruction revision and will be commercially available in mid-2025.
For the nine-month period that ended September 30, 2024, JNJ's sales to customers increased 4% year-over-year to $66.30 billion. Its gross profit rose 4.5% from the year-ago value to $45.96 billion. The company's net earnings from continuing operations amounted to $6.84 billion, representing a 15.7% increase from the same period last year. Also, its net earnings per share from continuing operations for the period increased 24.1% year-over-year to $4.38.
As per the updated guidance for the fiscal year 2024, JNJ forecasts operational sales between $89.40 billion and $89.80 billion, reflecting a 6.6% increase from 2023, primarily driven by recent acquisitions. The company also expects adjusted EPS between $9.88 and $9.98.
Street expects JNJ's revenue for the fiscal year (ended December 2024) to increase 4.3% year-over-year to $88.78 billion. Its EPS for the same period is expected to register a marginal growth from the prior year, settling at $9.96.
Shares of JNJ have declined marginally intraday, closing the last trading session at $143.78.
JNJ's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
JNJ has a B grade for Value, Stability, Sentiment, and Quality. It is ranked #11 out of 152 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/JNJ/">Click here</a> to see the additional ratings for JNJ (Growth and Momentum).
PepsiCo, Inc. (<a href="https://stocknews.com/stock/PEP/">PEP</a>)
PEP is a global beverage and convenience food company that engages in its manufacturing, marketing, distribution, and sales. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region.
On November 22, PEP announced its agreement to acquire the remaining 50% stake in Sabra Dipping Company and Obela. With this acquisition, PEP will become the sole owner of these refrigerated dips and spreads brands. This move should expand PEP's portfolio in the U.S. and Canada, meeting the growing demand for nutritious, simple foods.
In the same month, demonstrating its commitment to returning value to shareholders, the company declared the 52nd consecutive quarterly dividend of $1.355 per common share, a 7% increase year-over-year. This dividend will be paid on January 6, 2025.
PEP pays an annual dividend of $5.42, which translates to a yield of 3.61% at the current share price. Its four-year average dividend yield is 2.76%. Moreover, its dividend payouts have increased at a CAGR of 7.9% over the past three years.
During the third quarter of 2024, which ended on September 7, PEP's net revenues were $23.32 billion. Its total gross profit rose marginally from the year-ago value to $12.92 billion. Its non-GAAP operating profit stood at $4.18 billion, up 3.6% year-over-year, while its non-GAAP net income attributable amounted to $3.19 billion, representing an increase of 2.6% from the last year. Also, the company's non-GAAP EPS for the quarter increased 2.7% year-over-year to $2.31.
The consensus revenue estimate of $27.96 billion for the fiscal fourth quarter (ended December 2024) represents a marginal increase year-over-year. The consensus EPS estimate of $1.95 for the same quarter indicates a 9.4% improvement year-over-year. The company has an excellent earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
The stock has declined marginally intraday to close the last trading session at $149.91.
PEP's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has an A grade for Quality and a B for Growth. Within the B-rated <a href="https://stocknews.com/category/beverages/">Beverages</a> industry, it is ranked #11 out of 32 stocks. <a href="https://stocknews.com/stock/PEP/">Click here</a> to see PEP's ratings for Value, Momentum, Stability, and Sentiment.
Kimberly-Clark Corporation (<a href="https://stocknews.com/stock/KMB/">KMB</a>)
KMB is principally engaged in the manufacturing and marketing of personal care and consumer tissue products in the United States. The company operates through three segments: Personal Care; Consumer Tissue; and K-C Professional.
On January 3, buoyed by strong financial performance, the company paid its shareholders a quarterly dividend of $1.22 per share. KMB pays an annual dividend of $4.88, which translates to a yield of 3.74% at the current share price. Its four-year average dividend yield is 3.52%. Moreover, the company's dividend payouts have increased at a CAGR of 3.4% over the past five years.
KMB's revenue for the third quarter (ended September 30, 2024) amounted to $4.95 billion. It reported an operating profit of $1.15 billion, indicating a 49.1% growth from the prior-year quarter. The company's attributable non-GAAP net income came in at $617 million, and its EPS came in at $1.83 per share, up 4.6% and 5.2% year-over-year, respectively.
Analysts expect KMB's EPS for the fiscal year ended December 2024, 2025, to increase 11.4% year-over-year to $7.32. Its revenue for fiscal 2024 is expected to be $20 billion.
Over the past six months, the stock has surged 6.1%, closing the last trading session at $129.77.
It's no surprise that KMB has an overall rating of B, equating to a Buy in our POWR Ratings system. It has a B grade for Value, Sentiment, and Quality. Out of 55 stocks in the <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> industry, KMB is ranked #5.
Beyond what is stated above, we've also rated KMB for Growth, Momentum, and Stability. Get all KMB ratings <a href="https://stocknews.com/stock/KMB/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares were trading at $144.17 per share on Friday afternoon, up $0.15 (+0.10%). Year-to-date, JNJ has declined -0.31%, versus a 0.93% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/jnj-pep-kmb-3-dividend-aristocrats-every-investor-should-own/>3 Dividend Aristocrats Every Investor Should Own</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Dividend Aristocrats Every Investor Should Own

ABCL

ACCD

AGEN

ALSMY

ALTR

ALXO

AMGN

ARGX

ARLUF

BNTGF

BVHMF

CANF

CAPMF

CELH

CGON

COST

DXST

FBGL

FTNT

GLXZ

GMVHF

GOOG

GOOGL

HLICF

IMVT

INKT

INTU

ISRG

JSPR

KURA

MMYT

MNST

MSTR

MVRK

NFLX

NNRHF

NSRGY

NTDOY

PPRUF

PYPL

QBTS

REGN

RGTI

RHHBY

RHHVF

RLAY

SIEGY

SLXN

SMPL

SSNLF

TCHBF

TOPP

TSX:VG

TWLO

VWDRY

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Dean Omar Branham Shirley's Partners Named to List of 500 Leading Lawyers in America

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

Comments

Johnson & Johnson

ニュース

最新ニュース Johnson & Johnson (NYSE:JNJ) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル